CDKN2A and central nervous system cancer: With the recent 2021 update of the WHO Classification of Central Nervous System Tumors, homozygous deletions of CDKN2A/B are sufficient to classify meningiomas as CNS WHO grade 3 tumors regardless of histological grading [3].